SCHEMBL3141601

SCHEMBL3141601

CC(C)(C)OC(=O)C(C)(C)C(=O)OC(C)(C)C

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.79
ALDH1A1 P00352 2/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ELANE P08246 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CHRM1 P11229 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM3 P20309 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
GAA P10253 2/20 0.31
HMGCR P04035 1/20 0.30
TBXA2R P21731 1/20 0.30
ADRA1A P35348 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1735445 0.89 DGAT1 (1.00) DGAT1ALDH1A1ELANETDP1CA1
SCHEMBL8678863 0.87 DGAT1 (0.62) DGAT1
SCHEMBL998622 0.85 DGAT1 (0.61) DGAT1ALDH1A1USP2SMN1; SMN2ELANE
SCHEMBL16787839 0.85 DGAT1 (0.61) DGAT1USP2SMN1; SMN2GAA
SCHEMBL9784263 0.83 DGAT1 (0.58) DGAT1
SCHEMBL2597349 0.81 DGAT1 (0.56) DGAT1KMT2A
SCHEMBL307610 0.80 DGAT1 (0.55) DGAT1ALDH1A1USP2SMN1; SMN2ELANE
Hydrogen Peroxide SCHEMBL25411902 0.78 DGAT1 (0.52) DGAT1ALDH1A1USP2SMN1; SMN2ELANE
SCHEMBL362903 0.78 DGAT1 (0.52) DGAT1ALDH1A1USP2SMN1; SMN2ELANE
SCHEMBL20565054 0.78 DGAT1 (0.52) DGAT1ALDH1A1USP2SMN1; SMN2ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10031419-B2 Pattern forming method, composition kit and resist film, manufacturing method of electronic device using these, and electronic device FUJIFILM CORPORATION (JP) 2018-07-24 US disclosed
US-20160048075-A1 PATTERN FORMING METHOD, COMPOSITION KIT AND RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE USING THESE, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2016-02-18 US disclosed
US-8771916-B2 Actinic ray-sensitive or radiation-sensitive resin composition and pattern forming method using the same FUJIFILM CORPORATION (JP) 2014-07-08 US disclosed
EP-2307434-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARMACEUTICALS INC (US) 2014-02-12 EP disclosed
CN-103189396-A Method for producing solid catalyst component for olefin polymerization, catalyst for olefin polymerization, and olefin polymers TOHO TITANIUM CO LTD 2013-07-03 CN disclosed
EP-2476690-A1 Compounds and pharmaceutical compositions for the treatment of viral infections IDENIX Pharmaceuticals, Inc. (US) 2012-07-18 EP disclosed
US-20120171618-A1 ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING A PATTERN USING THE SAME FUJIFILM CORPORATION (JP) 2012-07-05 US disclosed
US-20110236828-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND PATTERN FORMING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2011-09-29 US disclosed
WO-2010014134-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS IDENIX PHARAMACEUTICALS, INC. (US) 2010-02-04 WO disclosed
US-20100003217-A1 Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections CRETTON-SCOTT ERIKA 2010-01-07 US disclosed
US-20100003217-A1 Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections CRETTON-SCOTT ERIKA 2010-01-07 US disclosed
US-20100003217-A1 Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections CRETTON-SCOTT ERIKA 2010-01-07 US disclosed
US-6331620-B1 AS POLYMERIZATION CATALYSTS FOR PRODUCING STEREOSPECIFIC HOMOPOLYMER OR COPOLYMER OF ALPHA-OLEFINS IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003217-A1 Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections HAVCR2, PYGL, GOT1 DGAT1 926/4885ALDH1A1 1905/4885USP2 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.